<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e>-initiating cells are responsible for <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> maintenance and relapse in solid and <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic cancers</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Although <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-initiating cells were initially believed to be mainly quiescent, rapidly proliferating tumorigenic cells were found in <z:hpo ids='HP_0003002'>breast cancer</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>In <z:hpo ids='HP_0003003'>colon cancer</z:hpo>, the proliferative activity of the tumorigenic population has not been defined, although it represents an essential parameter for the development of more effective therapeutic strategies </plain></SENT>
<SENT sid="3" pm="."><plain>Here, we show that tumorigenic <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cells can be found in a rapidly proliferating state in vitro and in vivo, both in human <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and mouse xenografts </plain></SENT>
<SENT sid="4" pm="."><plain>Inhibitors of polo-like kinase1 (Plk1), a mitotic kinase essential for cell proliferation, demonstrated maximal efficiency over other targeted compounds and chemotherapeutic agents in inducing <z:hpo ids='HP_0011420'>death</z:hpo> of <z:hpo ids='HP_0003003'>colon cancer</z:hpo>-initiating cells in vitro </plain></SENT>
<SENT sid="5" pm="."><plain>In vivo, Plk1 inhibitors killed CD133(+) <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cells leading to complete <z:mpath ids='MPATH_73'>growth arrest</z:mpath> of <z:hpo ids='HP_0003003'>colon cancer</z:hpo> stem cell-derived xenografts, whereas chemotherapeutic agents only slowed <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumor progression</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>While chemotherapy treatment increased CD133(+) cell proliferation, treatment with Plk1 inhibitors eliminated <z:hpo ids='HP_0000001'>all</z:hpo> proliferating <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-initiating cells </plain></SENT>
<SENT sid="7" pm="."><plain>Quiescent CD133(+) cells that survived the treatment with Plk1 inhibitors could be killed by subsequent Plk1 inhibition when they exited from quiescence </plain></SENT>
<SENT sid="8" pm="."><plain>Altogether, these results provide a new insight into the proliferative status of <z:e sem="disease" ids="C0009375" disease_type="Neoplastic Process" abbrv="">colon tumor</z:e>-initiating cells both in basal conditions and in response to therapy and indicate Plk1 inhibitors as potentially useful in the treatment of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>